OncoMatch/Triple-Negative Breast Cancer (TNBC)/BRCA1
Triple-Negative Breast Cancer (TNBC)BRCA1 Clinical Trials
Germline BRCA1 pathogenic variants are enriched in TNBC relative to other breast cancer subtypes, accounting for approximately 10–15% of TNBC cases, and confer sensitivity to PARP inhibition and platinum agents through homologous recombination deficiency. Olaparib and talazoparib are FDA-approved for germline BRCA1/2-positive HER2-negative metastatic breast cancer. Trials investigate PARP inhibitor combinations with immunotherapy, platinum chemotherapy, and antibody-drug conjugates including sacituzumab govitecan.
Top recruiting BRCA1 Triple-Negative Breast Cancer (TNBC) trials
Ranked by phase and US site count. See all 3 trials matched to your profile →
Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Okayama University
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Emory University
Browse other molecular targets with active Triple-Negative Breast Cancer (TNBC) trials.